Retatrutide
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Retatrutide?
Eli Lilly's investigational triple agonist (LY3437943), hitting GLP-1, GIP and glucagon receptors.
Phase 2 (NEJM 2023, Jastreboff et al., PMID 37366315) reported up to 24.2% weight reduction at 48 weeks. ⚠ The widely quoted 28.7% figure is from TRIUMPH-4 and comes from a Lilly TOPLINE PRESS RELEASE of 11 December 2025 — obesity with knee osteoarthritis, 12 mg, at 68 weeks — not from a peer-reviewed publication; the TRIUMPH papers indexed so far describe the trial DESIGN (PMID 41090431). The same release reported dysesthesia in 20.9% of the 12 mg arm against 0.7% on placebo. Not approved. ⛔ It is sold anyway, as “research peptide”, by sellers this register does not list.
Retatrutide: Lilly's triple agonist evidence →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Retatrutide comes up on this site
On GLP Watchdog, Retatrutide comes up in 4 research articles, 7 seller reviews, 21 FDA warning letters and 2 tools. Browse the FDA warning letters.
Research that discusses it
Tools that use it
Seller reviews that mention it
Connected terms
Other terms under Drugs and brands
Where the evidence lives
- Retatrutide: Lilly's triple agonist evidence
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers